OncoMatch/Clinical Trials/NCT07832292
A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
Official title: A Phase 2, Open-label, Multicenter, Single-arm Trial of JNJ-101556143, an Androgen Receptor-targeted Regulated Induced Proximity Targeting Chimera (RIPTAC™) Therapeutic in Participants With Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer
Is NCT07832292 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies JNJ-101556143 for prostatic neoplasms.
Treatment: JNJ-101556143 — The purpose of this study is to evaluate how well JNJ-101556143 works in participants with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced form of prostate cancer that has spread and no longer responds to hormone therapy. The study will measure the overall response (tumor shrinkage or disappearance) following treatment with JNJ-101556143.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
current or past history of distant metastasis (M1 disease). Local-regional disease including invasive disease of rectum, bladder, pelvis is allowed as long as participant has a current or past history of distant metastasis (M1 disease)
Demographics
Prior therapy
Must have received: androgen deprivation therapy (GnRH analog (agonist or antagonist), bilateral orchiectomy)
Prior bilateral orchiectomy or medical castration (receiving ongoing ADT with a Gonadotropin-Releasing Hormone (GnRH) analog [agonist or antagonist]) with castrate level of serum testosterone (<50 ng/dL or 1.7 nmol/L) prior to the first dose of trial intervention and must continue this therapy throughout the treatment phase
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Southern Urology LLC · Lafayette, Louisiana
- Greater Boston Urology · Plymouth, Massachusetts
- Associated Medical Professionals · Syracuse, New York
- The Conrad Pearson Clinic · Germantown, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07832292 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received androgen deprivation therapy.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages